Phase 3 Major Depression Trials Launched for Pimavanserin - MD Magazine

Phase 3 Major Depression Trials Launched for Pimavanserin  MD MagazineThe selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.